Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-101 in β-thalassemia major
NCT06065189Phase 1Completed
- Sponsor
- Children's Hospital of Fudan University
- Start
- Nov 2023
- Primary completion
- Aug 2025
- Modality
- Gene Silencing, Adenine Base Editors, Cytosine Base Editors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CS-101 in beta thalassemia, sponsored by Children's Hospital of Fudan University. Primary endpoints: Adverse Events at 180 days, Occurrence of engraftment at 42 days and 4 more. Started Nov 2023; status: completed.
02
Drugs
CS-101
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT06065189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065189.